ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.
- 10% revenue growth to $5.65 billion
- Acquisition of Noctrix Health expands sleep health portfolio
- MatrixCare business sale for $490 million underway
- Net income rises to $1.52 billion
- Ongoing patent litigation and regulatory risks
Financial Performance and Strategic Moves
ResMed Inc. (ASX:RMD) delivered a solid fiscal 2026 performance with net revenue climbing 10% to US$5.65 billion, driven by increased demand across its sleep and breathing health portfolio. Net income rose to US$1.52 billion, or US$10.43 per diluted share, up from US$1.40 billion the prior year. The company’s gross margin expanded to 61.1%, reflecting procurement and manufacturing efficiencies despite costs related to a field safety notification for Astral ventilators.
In a notable strategic expansion, ResMed completed its acquisition of Noctrix Health, LLC in June 2026 for US$335 million. Noctrix’s FDA De Novo classified wearable neurostimulation device targets restless legs syndrome, marking ResMed’s entry into an adjacent clinical sleep health market. This acquisition complements ResMed’s existing focus on obstructive sleep apnea (OSA) and chronic respiratory conditions, broadening its digital health footprint.
Simultaneously, ResMed announced an agreement to divest its MatrixCare business for US$490 million in cash, expected to close in early fiscal 2027. MatrixCare, part of ResMed’s Residential Care Software segment, generated approximately US$220 million in revenue and US$28 million in operating profit in fiscal 2026. The sale aligns with ResMed’s ongoing portfolio optimisation to concentrate on core growth areas of sleep, breathing, and connected home-based healthcare.
Product Innovation and Market Position
ResMed’s product suite remains anchored in cloud-connected continuous positive airway pressure (CPAP), bilevel, and ventilator devices, which accounted for over half of its net revenues. The company continues to innovate with AI-powered features such as the AirSense 11 platform, which offers touch screens, enhanced algorithms for therapy initiation, and over-the-air updates. Its myAir digital application, including the FDA-cleared Smart Comfort feature, supports personalised patient coaching to improve therapy adherence.
In diagnostics, ResMed expanded access to its NightOwl home sleep apnea test and strengthened its end-to-end care capabilities following its 2025 VirtuOx acquisition, which operates an independent diagnostic testing facility (IDTF) in the U.S. These moves position ResMed to capitalise on the underdiagnosed and undertreated sleep apnea market, estimated to affect hundreds of millions globally.
Regulatory and Competitive Risks
ResMed continues to navigate a complex regulatory landscape, with ongoing U.S. Food and Drug Administration (FDA) oversight and compliance obligations under HIPAA, GDPR, and emerging artificial intelligence (AI) regulations. The company’s recent acquisitions of VirtuOx and Noctrix introduce new layers of Medicare enrolment, billing, and fraud and abuse law compliance risks, including exposure to the federal Anti-Kickback Statute and Stark Law.
Patent litigation remains a live issue, with multiple suits filed by Cleveland Medical Devices and Fractus, S.A. alleging infringement of various patents related to connected devices and antenna technology. ResMed has engaged in inter partes review proceedings at the Patent Trial and Appeal Board, with mixed outcomes and ongoing appeals, underscoring the uncertainty in intellectual property protection within its sector.
Supply Chain and Macroeconomic Challenges
Supply chain disruptions and inflationary pressures remain a concern. ResMed sources components globally, including from single-source suppliers of configured parts and critical raw materials such as rare earth magnets, which face export controls and geopolitical risks. The company acknowledges that tariffs, trade restrictions, and currency fluctuations could impact costs and operational flexibility.
Global macroeconomic uncertainties, including inflation and geopolitical tensions, could affect demand and profitability. ResMed’s exposure to foreign exchange risk is managed through a comprehensive hedging program involving cross-currency swaps and forward contracts.
Capital Management and Shareholder Returns
ResMed maintains a strong liquidity position, with US$1.47 billion in cash and cash equivalents and US$1.5 billion available under its revolving credit facility as of June 30, 2026. The company repurchased approximately 2.9 million shares for US$705 million in fiscal 2026 and paid US$350 million in dividends, reflecting a commitment to shareholder returns. A quarterly dividend of US$0.66 per share was declared in August 2026, a 10% increase from the prior year.
Looking ahead, the company’s focus on AI-enabled digital health solutions, combined with its streamlined portfolio post-MatrixCare divestiture, aims to drive growth in the expanding sleep and breathing health markets. However, the trajectory will depend on successful integration of acquisitions, resolution of patent disputes, and adaptability to evolving reimbursement and regulatory environments.
Bottom Line?
ResMed’s FY2026 results underscore its leadership in sleep and breathing health, but patent battles and regulatory complexities pose ongoing challenges.
Questions in the middle?
- How will the integration of Noctrix influence ResMed’s clinical sleep health innovation pipeline?
- What impact will the MatrixCare divestiture have on ResMed’s digital health ecosystem and recurring revenue?
- How might evolving AI regulations reshape ResMed’s product development and compliance costs?